Regulus Therapeutics Announced The Dosing Of The First Patient In The Third Cohort Of The Phase 1B MAD Study Of RGSL8429 For Autosomal Dominant Polycystic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
Regulus Therapeutics has announced the dosing of the first patient in the third cohort of the Phase 1B MAD study of RGSL8429 for Autosomal Dominant Polycystic Kidney Disease.
November 02, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regulus Therapeutics' advancement into the third cohort of the Phase 1B MAD study for RGSL8429 may potentially impact the company's stock positively.
The advancement into the third cohort of the Phase 1B MAD study for RGSL8429 indicates progress in the company's clinical trials. This could potentially lead to positive investor sentiment, thereby positively impacting the stock price of Regulus Therapeutics.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100